Replies to post #65008 on SOHM Inc (SHMN)

[hardlesson]

If Night and Aguilar don't respond to your goading:
...let's remind them this way:

(11.21.23)
"The company is excited to announce the opening of a new facility in Carlsbad to meet the growing demand for its products. This facility will handle the orders that SOHM has received and expects to receive in the near future, while its main facility in downtown San Diego undergoes renovation to become fully operational. SOHM aims to complete the engineering batches produced in the San Diego facility by Q1 2024. This expansion is part of the company’s strategic plan to enhance its production capacity and efficiency.

As of this press release, the facility is near-final. Full cGMP manufacturing capacity is expected to be completed by December 2023."

“I am very proud to launch this facility with our SOHM team members. This Carlsbad facility is conveniently located right at the mid-way between two importing commercial hubs: Los Angeles and San Diego. Our location on major land shipping routes will play an important role in maintaining our competitive pricing edge in material sourcing and final products to our clients. Many people do not know this, but Carlsbad is also the home to many biotech and pharma companies who routinely rely on CDMO operators like SOHM for their bio-manufacturing needs,” says Dr. David Aguilar, COO.

Dr. Aguilar continues, “In 12 months, our Carlsbad facility will be expecting to manufacture 70% Rx and 30% OTC (over-the-counter) products. This facility will be able to meet all of our short-term SOHM brand Rx topical and OTC product manufacturing with 100% allocated to manufacture for CDMO clients whose orders are now arriving for year-end-2023.”

Key Milestone:
-- Engineering batch of topical branded generic completed within this financial year/2023
-- Initial released batch to client by 1Q 2024

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Announces-New-CDMO-GMP-Manufacturing-Facility-in-Carlsbad-California?id=422243

(12.5.23)
"The Company confirms it has the necessary requisites to become a branded-generic manufacturer, including: scientific personnel, FDA-approved manufacturing facilities, as well as an appropriate marketing and sales strategy.

The Company already has orders for its CDMO services and will launch two units to perform the manufacturing for these CDMO clients by 4Q-2023 and into 2024.

The Company will be manufacturing its ABBIE gene-editing kit at its manufacturing facilities in San Diego and Carlsbad. "

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Announces-Business-Outlook-for-2024?id=423706

(1.1.24)
"We are happy where things are today with the Year-end FDA approval of our Carlsbad manufacturing facility which will set our company up for a bright 2024 outlook."

We are happy where things are today with the Year-end FDA approval of our Carlsbad manufacturing facility which will set our company up for a bright 2024 outlook.$SHMN pic.twitter.com/tehLBtiVNs

— SOHM, Inc. (@sohminc) December 31, 2023

(1.9.24)
"We are thrilled to introduce this game-changing technology to the world," said Dr. David Aguilar, Ph.D., SOHM’s COO. "Graphene nanoparticles have the potential to revolutionize genome editing, offering unprecedented precision and efficiency. We believe this breakthrough will have a profound impact on human health and open up new possibilities for scientific research as more gene therapies continue to pass FDA approvals."

https://www.investorwire.com/newsarticle/?qmstory=4917662937161233
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Files-Provisional-Patent-on-ABBIEs-Smart-Gene-Editing-That-Uses-Latest-Enzymes-and-Guide-RNA-to-Resolve-Off-Target-?id=426610

_____
hL shmn Baby Pharma/Biotech at .0016. 2.7M MC.